Biohaven .(US:BHVN) Prnewswireยท2025-07-16 23:09Core Viewpoint - A class action lawsuit has been filed against Biohaven Ltd. on behalf of shareholders who purchased securities between March 24, 2023, and May 14, 2025, due to alleged misleading statements regarding the company's drug candidates [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Biohaven made false and misleading statements about the regulatory prospects of its drug troriluzole for treating spinocerebellar ataxia and the efficacy of BHV-7000 for bipolar disorder, which were overstated [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record, including recovering over $438 million for investors in 2019 alone [4]. - Investors can choose to remain absent from the class or select their own counsel, as no class has been certified yet [7].